

# CDSA<sup>2.0</sup> Comprehensive Digestive Stool Analysis 2.0

The Comprehensive Digestive Stool Analysis 2.0 (CDSA 2.0) is the most advanced non-invasive evaluation of specific gastrointestinal imbalances. In addition to identifying general dysfunction, this assay provides direct measures to pinpoint the diagnosis and treatment of patients with many digestive conditions such as Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD).

Digestive complaints are among the most common reasons that individuals seek medical care. Recent evidence now confirms that GI abnormalities are associated with many conditions outside the GI tract.

### General GI Dysfunction:

Indigestion  
Constipation  
Diarrhea  
Gas and Bloating  
Recent use of antibiotics  
GI infection/Dysbiosis

### Extra-intestinal Indications:

Osteoporosis  
Diabetes  
Arthritis  
Autoimmune disease  
Fibromyalgia  
Chronic Fatigue  
Abdominal Pain

### Specific GI Indications:

Post Inflammatory IBS  
Crohns Disease or Ulcerative Colitis (IBD)  
Family history of IBD  
Family history of Gastrointestinal cancers  
Pancreatic Insufficiency  
Gallstones

### Digestion/Absorption Markers:

*(Pancreatic Elastase, Putrefactive SCFAs, n-Butyrate)*

- Direct measure of Pancreatic Digestive Enzyme output without interference from digestive supplements, changes in stool transit time or marker variability. Low levels of digestive enzyme output are associated with intestinal and Extra-intestinal conditions.

### Gut Immunology Markers:

*(Calprotectin, Eosinophil Protein X)*

- This quantitative analysis identifies mild, moderate or severe inflammation within the GI tract. Elevations of these markers are associated with infection (bacterial, viral, & parasitic), food allergy, NSAID enteropathy, IBD and neoplasia.  
- GI inflammation is associated with Intestinal and Extra-intestinal conditions.

### Metabolic Markers:

*(Short Chain Fatty Acids, pH, Beta-glucuronidase, Bile Acids)*

- Abnormal levels of Short Chain Fatty Acids may indicate alterations in gut flora, insufficient dietary fiber, altered transit time and small bowel bacteria overgrowth.  
- The chemistry markers identify imbalances that are associated with increased toxic burden within the colon, increasing long-term risk for colon and breast cancers.

### Microbiology Markers:

*(Bacteriology, Mycology)*

- Quantitative measures of the beneficial flora Lactobacillus and Bifidobacterium  
- Quantitative measures of additional flora, including strict pathogenic bacteria and potentially pathogenic and bacteria and yeast.  
- An imbalance in GI flora is associated with Intestinal and Extra-intestinal conditions.

### Parasitology:

*(EIA and microscopic evaluation)*

- With the highest documented recovery rates (22% positivity rate), this Parasitology exam quantifies all ova and parasites identified.  
- Includes microscopic evaluation for yeast and blood cells.

### •Analytes:

Pancreatic Elastase 1  
Putrefactive SCFAs  
Short Chain Fatty Acids  
n-Butyrate  
Calprotectin  
Eosinophil Protein X  
pH  
Beta-glucuronidase  
Bile Acids  
Bacteriology  
Mycology  
EIA  
microscopic evaluation

### •Specimen Requirement:

5cc stool in each vial-3 SAF,  
2 Cary Blair, 1 Formalin; 40ml stool  
in yellow-top cup; 20 ml stool in  
clean vial. May be random stool or  
purge.

### •Before Patient Takes this Test:

- Avoid antibiotics, antifungals,  
laxatives, and anti-diarrheals  
(for 3 days)  
- Avoid use of non-steroidal  
anti-inflammatories (for 2 days)  
- See instructions inside test kit for  
more details



Genova  
Diagnostics®

Improving Healthcare for Chronic Disease



# Comprehensive Digestive Stool Analysis 2.0



Patient: **SAMPLE PATIENT**

Age: 56  
Sex: M  
MRN:

Order Number:

Completed: June 27, 2007  
Received: June 21, 2007  
Collected: June 20, 2007

## Digestion/Absorption

| Analyte                        | Result | Reference Range    |
|--------------------------------|--------|--------------------|
| 1. Pancreatic Elastase 1*      | 284    | >= 201 mcg/g       |
| 2. Putrefactive SCFAs (Total*) | 4.6    | 1.3-8.6 micromol/g |

\*Total values equal the sum of all measurable parts.

## Digestion/Absorption

Digestion encompasses the functional activities of: mastication, gastric acid production, pancreatic activity, bile production and brush border maintenance. Absorption depends on all of the above actions, as well as a healthy gut mucosal barrier.

## Gut Immunology

| Analyte                 | Result | Reference Range |
|-------------------------|--------|-----------------|
| 3. Eosinophil Protein X | >22.6  | <= 7.0 mcg/g    |
| 4. Calprotectin         | >500   | <= 50 mcg/g     |

## Gut Immunology

These immune markers are derived from the activation and degranulation of eosinophils (EPX) and neutrophils (calprotectin). EPX reflects inflammation and tissue damage and can be elevated in food allergies, celiac disease, helminthic infection, IBD and cancer. Calprotectin is inflammation specific and can elevate with infection or post infectious IBS, NSAID enteropathy, IBD and cancer. Children with chronic diarrhea from cows milk allergy or multiple food allergies may also have increased calprotectin.

## Metabolic

| Analyte                      | Result | Reference Range    |
|------------------------------|--------|--------------------|
| 5. Beneficial SCFAs (Total*) | 115.3  | >= 13.6 micromol/g |
| 6. n-Butyrate                | 21.3   | >= 2.5 micromol/g  |
| 7. pH*                       | 5.7    | 6.1-7.9            |
| 8. Beta-glucuronidase        | 317    | 337-4,433 U/g      |
| <b>Bile Acids</b>            |        |                    |
| 9. Lithocholic acid (LCA)    | 1.30   | 0.65-5.21 mg/g     |
| 10. Deoxycholic acid (DCA)   | 1.25   | 0.67-6.76 mg/g     |
| 11. LCA / DCA Ratio          | 1.04   | 0.39-2.07          |

\*Total values equal the sum of all measurable parts.

## Metabolic

Gut metabolism is representative of the bacterial milieu, primarily through the presence of commensal bacteria. Metabolic activities include: mucous production, vitamin synthesis and absorption, deconjugation of steroid hormones and bile acids, fat regulation, and SCFA metabolism. These metabolic activities require a normal population of commensal bacteria without active bacterial, viral, or parasitic infection.

This test reveals important information about:

- **Calprotectin** as an important marker of gastrointestinal inflammation. It can help to distinguish IBD & IBS, as well as other inflammatory conditions.
- **Pancreatic Elastase** to distinguish maldigestion from pancreatic versus gastric sources.
- **Decreased exocrine pancreatic function** is linked to gallstones, diabetes, osteoporosis, and autoimmune diseases.
- **Gastrointestinal tract inflammation** occurring in response to food allergy, protein-sensitive enteropathy, helminthic infection, IBD, allergic colitis, or neoplasm.
- **Bile Acids** play an important role in fat emulsion and fat absorption. High levels of some bile acids are associated with increased toxin buildup, increased risk of gallstones, and gastro-intestinal neoplasms.



Genova Diagnostics®

Improving Healthcare for Chronic Disease

63 Zillicoa Street  
Asheville, NC 28801-1074

© Genova Diagnostics  
CLIA Lic. #34D0655571 - Medicare Lic. #34-8475

CD201 RMS 2505 Rev 5

For test kits, clinical support, or more information contact:

Client Services  
Genova Diagnostics  
63 Zillicoa St.  
Asheville, NC 28801-1074  
800-522-4762 • Fax: 828-252-9303

More detailed publications with references are also available: [www.GDX.net](http://www.GDX.net)